Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Discovery of a Stress-Activated Protein Kinase Inhibitor for Lymphatic Filariasis.

Tummalapalli SR, Bhat R, Chojnowski A, Prorok M, Kreiss T, Goldberg R, Canan S, Hawryluk N, Mortensen D, Khetani V, Zeldis J, Siekierka JJ, Rotella DP.

ACS Med Chem Lett. 2018 Feb 9;9(3):210-214. doi: 10.1021/acsmedchemlett.7b00477. eCollection 2018 Mar 8.

2.

Expression, purification and enzymatic characterization of Brugia malayi dihydrofolate reductase.

Perez-Abraham R, Sanchez KG, Alfonso M, Gubler U, Siekierka JJ, Goodey NM.

Protein Expr Purif. 2016 Dec;128:81-5. doi: 10.1016/j.pep.2016.08.012. Epub 2016 Aug 18.

PMID:
27544923
3.

Human p38 mitogen-activated protein kinase inhibitor drugs inhibit Plasmodium falciparum replication.

Brumlik MJ, Nkhoma S, Kious MJ, Thompson GR 3rd, Patterson TF, Siekierka JJ, Anderson TJ, Curiel TJ.

Exp Parasitol. 2011 Jun;128(2):170-5. doi: 10.1016/j.exppara.2011.02.016. Epub 2011 Feb 19.

4.

The role of a Brugia malayi p38 MAP kinase ortholog (Bm-MPK1) in parasite anti-oxidative stress responses.

Patel A, Chojnowski AN, Gaskill K, De Martini W, Goldberg RL, Siekierka JJ.

Mol Biochem Parasitol. 2011 Apr;176(2):90-7. doi: 10.1016/j.molbiopara.2010.12.008. Epub 2010 Dec 24.

PMID:
21185874
5.

Apicomplexa, trypanosoma and parasitic nematode protein kinases as antiparasitic therapeutic targets.

Liotta F, Siekierka JJ.

Curr Opin Investig Drugs. 2010 Feb;11(2):147-56. Review.

PMID:
20112164
6.

HIV-1 Nef-induced FasL induction and bystander killing requires p38 MAPK activation.

Muthumani K, Choo AY, Hwang DS, Premkumar A, Dayes NS, Harris C, Green DR, Wadsworth SA, Siekierka JJ, Weiner DB.

Blood. 2005 Sep 15;106(6):2059-68. Epub 2005 May 31.

7.

Suppression of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor.

Muthumani K, Wadsworth SA, Dayes NS, Hwang DS, Choo AY, Abeysinghe HR, Siekierka JJ, Weiner DB.

AIDS. 2004 Mar 26;18(5):739-48.

PMID:
15075508
8.

Imidazopyrimidines, potent inhibitors of p38 MAP kinase.

Rupert KC, Henry JR, Dodd JH, Wadsworth SA, Cavender DE, Olini GC, Fahmy B, Siekierka JJ.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50.

PMID:
12565927
9.

Kinetics of small molecule inhibitor binding to p38 kinase.

Thurmond RL, Wadsworth SA, Schafer PH, Zivin RA, Siekierka JJ.

Eur J Biochem. 2001 Nov;268(22):5747-54.

10.

RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.

Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, Wu W, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Wachter MP, Siekierka JJ.

J Pharmacol Exp Ther. 1999 Nov;291(2):680-7.

PMID:
10525088
12.

Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice.

Kanakaraj P, Ngo K, Wu Y, Angulo A, Ghazal P, Harris CA, Siekierka JJ, Peterson PA, Fung-Leung WP.

J Exp Med. 1999 Apr 5;189(7):1129-38.

14.

Potent inhibitors of the MAP kinase p38.

Henry JR, Rupert KC, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, Schafer PH, Siekierka JJ.

Bioorg Med Chem Lett. 1998 Dec 1;8(23):3335-40.

PMID:
9873730
15.

The development of novel and selective p56lck tyrosine kinase inhibitors.

Bullington JL, Cameron JC, Davis JE, Dodd JH, Harris CA, Henry JR, Pellegrino-Gensey JL, Rupert KC, Siekierka JJ.

Bioorg Med Chem Lett. 1998 Sep 22;8(18):2489-94.

PMID:
9873567
16.

6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1H-pyrrolo[2, 3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor.

Henry JR, Rupert KC, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Schafer PH, Siekierka JJ.

J Med Chem. 1998 Oct 22;41(22):4196-8. No abstract available.

PMID:
9784093
17.
18.

Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production.

Kanakaraj P, Schafer PH, Cavender DE, Wu Y, Ngo K, Grealish PF, Wadsworth SA, Peterson PA, Siekierka JJ, Harris CA, Fung-Leung WP.

J Exp Med. 1998 Jun 15;187(12):2073-9.

19.

Yeast immunophilins: purification and assay of yeast FKBP12.

Wiederrecht G, Siekierka JJ.

Methods Enzymol. 1998;290:74-84. No abstract available.

PMID:
9534152
20.
21.

Editorial

Siekierka JJ.

Methods. 1996 Apr;9(2):145. No abstract available.

PMID:
8812654
22.

Structure and mapping of the human thymopoietin (TMPO) gene and relationship of human TMPO beta to rat lamin-associated polypeptide 2.

Harris CA, Andryuk PJ, Cline SW, Mathew S, Siekierka JJ, Goldstein G.

Genomics. 1995 Jul 20;28(2):198-205.

PMID:
8530026
23.

Three distinct human thymopoietins are derived from alternatively spliced mRNAs.

Harris CA, Andryuk PJ, Cline S, Chan HK, Natarajan A, Siekierka JJ, Goldstein G.

Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6283-7.

24.
25.

Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes.

Morice WG, Wiederrecht G, Brunn GJ, Siekierka JJ, Abraham RT.

J Biol Chem. 1993 Oct 25;268(30):22737-45.

26.

Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes.

Morice WG, Brunn GJ, Wiederrecht G, Siekierka JJ, Abraham RT.

J Biol Chem. 1993 Feb 15;268(5):3734-8.

27.

Characterization of high molecular weight FK-506 binding activities reveals a novel FK-506-binding protein as well as a protein complex.

Wiederrecht G, Hung S, Chan HK, Marcy A, Martin M, Calaycay J, Boulton D, Sigal N, Kincaid RL, Siekierka JJ.

J Biol Chem. 1992 Oct 25;267(30):21753-60.

28.

FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond.

Siekierka JJ, Sigal NH.

Curr Opin Immunol. 1992 Oct;4(5):548-52. Review.

PMID:
1384551
29.

The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin.

Dumont FJ, Staruch MJ, Koprak SL, Siekierka JJ, Lin CS, Harrison R, Sewell T, Kindt VM, Beattie TR, Wyvratt M, et al.

J Exp Med. 1992 Sep 1;176(3):751-60.

30.

Yeast FKBP-13 is a membrane-associated FK506-binding protein encoded by the nonessential gene FKB2.

Nielsen JB, Foor F, Siekierka JJ, Hsu MJ, Ramadan N, Morin N, Shafiee A, Dahl AM, Brizuela L, Chrebet G, et al.

Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7471-5.

31.

Isolation of a human cDNA encoding a 25 kDa FK-506 and rapamycin binding protein.

Wiederrecht G, Martin MM, Sigal NH, Siekierka JJ.

Biochem Biophys Res Commun. 1992 May 29;185(1):298-303.

PMID:
1376117
32.

Is FKBP involved in the immunosuppressive and/or toxic mechanism of action of FK 506?

Sigal NH, Dumont FJ, Siekierka JJ, Wiederrecht G, Parent SA, Brizuela L.

Transplant Proc. 1991 Dec;23(6):2846-9. Review. No abstract available.

PMID:
1721295
33.

Potential roles of other FK 506-binding proteins in mediating the effects of FK 506.

Siekierka JJ, Wiederrecht G, Cryan J, Hung SH, Comisky M, Sigal NH.

Transplant Proc. 1991 Dec;23(6):2720-1. No abstract available.

PMID:
1721256
34.

FKBP, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity.

Cryan J, Hung SH, Wiederrecht G, Sigal NH, Siekierka JJ.

Biochem Biophys Res Commun. 1991 Oct 31;180(2):846-52.

PMID:
1719972
35.

Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A.

Sigal NH, Lin CS, Siekierka JJ.

Transplant Proc. 1991 Apr;23(2 Suppl 2):1-5. No abstract available.

PMID:
1712132
36.

FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes.

Lin CS, Boltz RC, Siekierka JJ, Sigal NH.

Cell Immunol. 1991 Apr 1;133(2):269-84.

PMID:
1707760
37.

Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A?

Sigal NH, Dumont F, Durette P, Siekierka JJ, Peterson L, Rich DH, Dunlap BE, Staruch MJ, Melino MR, Koprak SL, et al.

J Exp Med. 1991 Mar 1;173(3):619-28.

38.

FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins.

Wiederrecht G, Brizuela L, Elliston K, Sigal NH, Siekierka JJ.

Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):1029-33. Erratum in: Proc Natl Acad Sci U S A 1991 Apr 1;88(7):2967.

39.

The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase.

Siekierka JJ, Wiederrecht G, Greulich H, Boulton D, Hung SH, Cryan J, Hodges PJ, Sigal NH.

J Biol Chem. 1990 Dec 5;265(34):21011-5.

40.

Observations on the mechanism of action of FK-506. A pharmacologic probe of lymphocyte signal transduction.

Sigal NH, Siekierka JJ, Dumont FJ.

Biochem Pharmacol. 1990 Nov 15;40(10):2201-8. Review. No abstract available.

PMID:
1700909
41.
42.
43.

The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes.

Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, Degudicibus S, Siekierka JJ, Chin J, Hutchinson NI.

J Immunol. 1989 Jul 15;143(2):718-26.

PMID:
2472451
44.

Radioiodination of interleukin 2 to high specific activities by the vapor-phase chloramine T method.

Siekierka JJ, DeGudicibus S.

Anal Biochem. 1988 Aug 1;172(2):514-7.

PMID:
3263816
45.

The placental transfer of lead-chelate complexes in the rat.

McClain RM, Siekierka JJ.

Toxicol Appl Pharmacol. 1975 Mar;31(3):443-51. No abstract available.

PMID:
1145629
46.

The effects of various chelating agents on the teratogenicity of lead nitrate in rats.

McClain RM, Siekierka JJ.

Toxicol Appl Pharmacol. 1975 Mar;31(3):434-42. No abstract available.

PMID:
806992

Supplemental Content

Loading ...
Support Center